STTK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Shattuck Labs Inc (STTK) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock is currently trading pre-market at $7.73, and analysts have significantly raised price targets, indicating strong confidence in the company's lead asset SL-325. Despite weak financial performance, the company's innovative pipeline and upcoming Phase 1 data in Q2 2026 present a favorable risk/reward profile. Technical indicators also support a bullish outlook.
The MACD is positive at 0.0246, indicating bullish momentum. The RSI is neutral at 65.863, and the moving averages (SMA_5 > SMA_20 > SMA_200) are bullish. The stock is trading above its pivot level of 7.455, with resistance at 8.086 and support at 6.825, suggesting potential for upward movement.
Analysts have raised price targets significantly, with H.C. Wainwright increasing the target to $18 and maintaining a Buy rating. Upcoming Phase 1 data for SL-325 in Q2 2026 is expected to highlight differentiation and efficacy. The company's approach to inflammatory bowel disease treatment is considered highly innovative and differentiated.
No significant hedge fund or insider trading trends have been observed recently.
In Q4 2025, revenue remained at $0, with no YoY growth. Net income dropped to -$12.59 million, down -32.58% YoY, and EPS decreased to -0.12, a -67.57% YoY decline. However, gross margin remains at 100%.
Analysts are bullish on STTK, with multiple firms raising price targets significantly. H.C. Wainwright raised the target to $18, Wedbush to $8, Needham to $14, and Piper Sandler to $15, all citing confidence in SL-325's potential and differentiation. Analysts recommend owning the stock ahead of Phase 1 data in Q2 2026.
